Gapping up
In reaction to earnings/guidance:
- PCRX +8.2% (reports preliminary 2018 net Exparel sales of $331 million)
M&A news:
- CELG +33.3% (to be acquired by Bristol-Myers Squibb (BMY) for $102.43/share in cash & stock)
- ZEUS +0.5% (acquires McCullough Ind.; terms not disclosed; deal marks entry into branded metal products manufacturing)
Other news:
- DBVT +15.9% (announces changes to leadership team -- interim Chief Medical Officer named)
- PGNX +3.5% (Point72 discloses 5.7% passive stake)
- LSCC +3% (announced the appointment of Sherri Luther as Chief Financial Offer, effective immediately)
- TEVA +2.2% (resolves generic cinacalcet HCl product dispute with Amgen (AMGN))
- IRWD +0.7% (Ironwood Pharma and Allergan announce settlement with Mylan resolving LINZESS/linaclotide patent litigation)
Analyst comments:
- CSIQ +4.6% (upgraded to Buy from Neutral at Goldman)
- GILD +3.2% (upgraded to Outperform from Perform at Oppenheimer)
- FSLR +2.4% (upgraded to Buy from Neutral at Goldman)
- EMR +0.8% (upgraded to Outperform from Neutral at Credit Suisse)
